Skip to main content

Table 2 Viability of pancreas cancer cell lines following treatment with sigma-2 ligands and gemcitabine.

From: The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine

Gemcitabine

-

+

-

+

-

+

-

+

Cell Line

DMSO

SV119

SW43

SRM

Panc02

100

50 ± 3

79 ± 7

39 ± 1

24 ± 5

14 ± 2

6 ± 0

2 ± 2

Panc1

100

47 ± 5

81 ± 6

41 ± 5

43 ± 5

19 ± 4

8 ± 4

3 ± 3

BxPC3

100

71 ± 1

66 ± 2

52 ± 1

43 ± 4

33 ± 4

8 ± 2

2 ± 1

Cfpac

100

40 ± 8

88 ± 4

40 ± 4

60 ± 6

21 ± 7

8 ± 5

4 ± 2

  1. Pancreas cancer cell lines were pretreated with gemcitabine (0.5 uM) or vehicle for 24 hours followed by sigma-2 ligand (25 uM) treatment for 18 hours and viability represented as percentage relative to vehicle, (mean ± SEM), n ≥ 3.
Back to article page

Molecular Cancer

ISSN: 1476-4598